Galectin-3 and new-onset CKD: Marker or mediator?

Journal of the American Society of Nephrology

Volumn 24, Issue 9, 2013, Pages 1342-1344

  Ravani, Pietro ^a,b   Barrett, Brendan J ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GALECTIN 3;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIAGNOSTIC VALUE; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; KIDNEY FIBROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 84884301845     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013050552     Document Type: Review

References (21)

1. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629-636, 2001
2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J Am Soc Nephrol 15: 1307-1315, 2004
3. Drey N, Roderick P, Mullee M, Rogerson M: A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. AmJ Kidney Dis 42: 677-684, 2003
4. Huisman RM: The deadly risk of late referral. Nephrol Dial Transplant 19: 2175-2180, 2004
5. Tonelli M, Muntner P, Lloyd A, Manns BJ, James MT, Klarenbach S, Quinn RR,WiebeN, Hemmelgarn BR; Alberta KidneyDiseaseNetwork: Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: A cohort study. Ann InternMed 154: 12-21, 2011
6. Ioannidis JP, Panagiotou OA: Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305: 2200-2210, 2011
7. O'Seaghdha CM, Hwang SJ, Ho JE, Vasan RS, Levy D, Fox CS: Elevated galectin-3 precedes the development of CKD. J Am Soc Nephrol 24: 1470-1477, 2013
8. de Boer RA, Voors AA,MuntendamP, vanGilstWH, van Veldhuisen DJ: Galectin-3: A novel mediator of heart failure development and progression. Eur J Heart Fail 11: 811-817, 2009
9. NachtigalM,Ghaffar A, Mayer EP:Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 172: 247-255, 2008
10. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR: Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 28: 433-440, 2008
11. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, Liu FT, Lukic ML: Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocininduced diabetes in mice. Clin Immunol 130: 83-88, 2009
12. del Pozo V, Rojo M, Rubio ML, Cortegano I, Cárdaba B, Gallardo S, Ortega M, Civantos E, López E, Martín-Mosquero C, Peces-Barba G, Palomino P, González-Mangado N, Lahoz C: Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigenchallenged rats through interleukin-5 gene downregulation. Am J Respir Crit Care Med 166: 732-737, 2002
13. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, Haslett C, Simpson KJ, Sethi T: Galectin-3 regulates myofibroblast activation and hepatic fibrosis. ProcNatlAcad SciU SA103: 5060-5065, 2006
14. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 172: 288-298, 2008
15. Tang WH, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, KleinAL: Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.AmJCardiol 108: 385-390, 2011
16. Ho JE, Liu C, Lyass A, Courchesne P, PencinaMJ, Vasan RS, LarsonMG, Levy D: Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 60: 1249-1256, 2012
17. de Boer RA, LokDJ, Jaarsma T, van derMeer P, VoorsAA,Hillege HL, van Veldhuisen DJ: Predictive value of plasmagalectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43: 60-68, 2011
18. Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN, Schnitzbauer A, Schäffler A, Aslanidis C, Schölmerich J, Buechler C: Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 95: 1404-1411, 2010
19. Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Tubulointerstitial damage and progression of renal failure. Kidney Int Suppl (99): S82-S86, 2005
20. Rigatto C, Barrett BJ: Biomarkers and surrogates in clinical studies. Methods Mol Biol 473: 137-154, 2009
21. Glinsky VV, Raz A: Modified citrus pectin anti-metastatic properties: One bullet, multiple targets. Carbohydr Res 344: 1788-1791, 2009